SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Correlative Science Protocol Development

leigh-duffy avatar
leigh-duffy
16 diapositives · 323 Views · Nov 06, 2014

At the CALGB Fall Committee Meeting in October 2006, Dr. Paula N. Friedman discussed the essential inclusion of correlative science (CS) information in clinical protocols. This presentation emphasizes the importance of addressing CS from the outset, illustrating how biological markers relate to therapy, supporting hypotheses, and utilizing preclinical data. Key aspects include detailed sample descriptions, assay methodologies, and certification of testing labs. By ensuring clarity in protocol documents, the meeting aims to enhance patient registration, proper sample collection, and future scientific contributions.

Correlative Science Protocol Development - slide 1
01 / 16Correlative Science Protocol Development
1 / 17

Télécharger la présentation

Correlative Science Protocol Development
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Correlative Science Protocol Development Paula N. Friedman, PhD Director, Biospecimen & Correlative Science Operations CALGB Fall Committee Meeting October 2006

  2. Where in the protocol should there be information about CS? • Introduction • Objectives • Sample Submission • CS Methods* • Statistical Considerations • Model Consent Form CALGB Fall Committee Meeting October 2006

  3. When in the process does CS need to be considered? Right from the start!! CALGB Fall Committee Meeting October 2006

  4. Things that should be included in the concept/protocol • The biologic rationale for studying the proposed marker(s). • Why are the markers relevant to study and how are they related to the therapy? • The specific hypotheses behind the proposed correlative studies. • What is it you are expecting to find and why? CALGB Fall Committee Meeting October 2006

  5. Things that should be included in the concept/protocol • Preclinical data that supports the proposal to look at the markers* • Preliminary data from other clinical trials that have looked at the markers* • Statistical considerations • The proposed contributions that this study will make to the field • Future plans for analysis of the markers if this study accomplishes its goals *references should be provided CALGB Fall Committee Meeting October 2006

  6. Things that should be included in the protocol • A detailed description of the types of samples to be collected and the timepoints (Table). • Any information about the stability of the marker under the collection conditions proposed • A description of the assay method and the reason for selecting it. • A summary table that includes assay type, sample type, key contact and institution CALGB Fall Committee Meeting October 2006

  7. CALGB Fall Committee Meeting October 2006

  8. Correlative Science Table CALGB Fall Committee Meeting October 2006

  9. CALGB Fall Committee Meeting October 2006

  10. Things that should be included in the protocol • The technical performance of the assay • Qualitative vs. quantitative • Accuracy (Sens, Spec, PPV, NPV) • Reproducibility (day and user) • Sources of variability and how variability will be minimized • A description of the positive and negative controls to be used • Method of scoring that will be used. • The certification of the testing lab • CLIA and/or CAP • If not, how the QA/QC will be handled CALGB Fall Committee Meeting October 2006

  11. Why is this so important? • If the sample collection is not accurately described then the appropriate samples will not be collected. • Example: CALGB 80101- The companion study, CALGB 150205, calls for analysis of IGF-1, IGF-2 and IGFBP-3 in serum but the protocol is not clear as to the collection of serum samples. • We collected plasma at the bank from the blood tube designated for PET and some markers can be done on plasma but not all • While going to all the trouble of collecting these valuable samples we need to make sure that they are being utilized fully. • We need to consider using the sample for proteomics (discovery) CALGB Fall Committee Meeting October 2006

  12. Why is this all so important? • If the protocol text is not clear then a patient may not be registered to the companion, samples may not be collected appropriately and sent to the bank and consent may not be obtained or correctly recorded. • Example: CALGB 60401 - PET companion to CALGB 80303 CALGB Fall Committee Meeting October 2006

  13. The Reality CALGB Fall Committee Meeting October 2006

  14. The Reality CALGB Fall Committee Meeting October 2006

  15. What we are doing to make the system work better • Summary tables in protocols • SOPs for sample collection • Standardized consent questions • “Real-time” monitoring of sample submission • Patient brochures on the importance of sample donation • New committee - Biospecimen & CS Advisory • Reference labs that are CLIA/CAP certified CALGB Fall Committee Meeting October 2006

  16. Contact Information Paula N. Friedman, PhD CALGB Central Office (773)702-4694 pfriedman@calgb.org CALGB Fall Committee Meeting October 2006